Loading stock data…
Pfizer, Inc. (PFE)
$24.55-0.03 (-0.14%)
Market OpenUpdated 3:54 PM EDT
Pfizer Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pfizer Inc. in the Healthcare sector is trading at $24.55 with a market capitalization of $139.9B. Wall Street consensus targets $28.75 (26 analysts), implying a +17.1% move over the next 12 months. The stock is currently 15% below its 52-week high of $28.75, remaining 3.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +17.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.45B↓ | $17.56B↑ | $16.65B↑ | $14.65B↑ | $13.71B |
| Gross Profit | $10.90B↓ | $12.29B↓ | $12.48B↑ | $10.88B | $10.87B |
| Operating Income | $4.13B↑ | $3.48B↓ | $4.14B↑ | $3.77B↓ | $4.42B |
| Net Income | $2.69B↑ | -$1.65B↓ | $3.54B↑ | $2.91B↓ | $2.97B |
Peer Comparison
JNJUNHABBV
Fundamentals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$139.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Strong income play. Yield provides a meaningful total return floor.
7.01%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.31%
Volume
Today's trading volume
21.41M
Recent News
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring
Could it become as successful in this niche as it was in the coronavirus vaccine market?
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer
Income seekers shouldn't give up on the stock yet.
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.
Verizon Was Booted From the Dow – 5 Dividend Giants Got the Same Treatment and Eventually Soared
Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.